← Leaderboards
Edith Tzeng
Veterans Health Administration
$11,643,874
Attributed
$13,209,423
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,209,423 · 7
VA$0 · 3
By mechanism
T32$6,709,769 · 1
R01$3,949,802 · 2
U01$1,646,257 · 1
R56$454,539 · 1
R33$344,056 · 1
R29$105,000 · 1
Top collaborators
- Yadong Wang7 shared
- David Alan Vorp1 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Luke Packard Brewster$4,406,085
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsOperative Surgical ProceduresMorbidity - Disease RateAtherosclerosisPropertyAffectNitric OxideNitric Oxide SynthaseInflammationResearch TrainingImpairmentDiabetes MellitusHyperplasiaArteriesCardiovascular SystemRestenosisCell ProliferationNon-Insulin-Dependent Diabetes MellitusFunctional DisorderDoseCostEventBypassIncidence
Grant awards (50)
Vascular Surgery Research Training (VascTrain)$599,709
T32 · FY2025 · HL · contact PI
Preclinical Optimization and Design for Manufacturability of Immunoregulatory TEVGs$344,056
R33 · FY2025 · HL
Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE_IC)$0
I01 · FY2025 · VA · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$575,008
R01 · FY2024 · HL
Vascular Surgery Research Training (VascTrain)$339,068
T32 · FY2024 · HL · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$84,674
R01 · FY2024 · HL
Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE_IC)$0
I01 · FY2024 · VA · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$622,818
R01 · FY2023 · HL
Vascular Surgery Research Training (VascTrain)$552,828
T32 · FY2023 · HL · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$85,912
R01 · FY2023 · HL
Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE_IC)$0
I01 · FY2023 · VA · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$683,293
R01 · FY2022 · HL
Vascular Surgery Research Training (VascTrain)$539,778
T32 · FY2022 · HL · contact PI
Research Supplements to Promote Diversity in Vascular Graft Research$87,070
R01 · FY2022 · HL
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2022 · VA · contact PI
Elastic, Degradable Vascular Grafts with Helical Microfibers$648,267
R01 · FY2021 · HL
Vascular Surgery Research Training (VascTrain)$516,626
T32 · FY2021 · HL · contact PI
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2021 · VA · contact PI
Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE_IC)$0
I01 · FY2021 · VA · contact PI
Vascular Surgery Research Training (VascTrain)$511,571
T32 · FY2020 · HL · contact PI
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2020 · VA · contact PI
Vascular Surgery Research Training (VascTrain) Program$259,931
T32 · FY2019 · HL · contact PI
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2019 · VA · contact PI
Engineering Biologic Topography into Vascular Grafts$454,539
R56 · FY2018 · HL · contact PI
Vascular Surgery Research Training (VascTrain) Program$443,606
T32 · FY2018 · HL · contact PI
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2018 · VA · contact PI
Vascular Surgery Research Training (VascTrain) Program$426,240
T32 · FY2017 · HL · contact PI
Xanthine oxidoreductase in impaired diabetic wound healing.$0
I01 · FY2017 · VA · contact PI
Vascular Surgery Research Training (VascTrain) Program$421,600
T32 · FY2016 · HL · contact PI
Vascular Surgery Research Training (VascTrain) Program$417,051
T32 · FY2015 · HL · contact PI
Vascular Surgery Research Training$327,050
T32 · FY2014 · HL · contact PI
Carbon monoxide mediated inhibition of intimal hyperplasia$0
I01 · FY2014 · VA · contact PI
Vascular Surgery Research Training$391,215
T32 · FY2013 · HL · contact PI
Carbon monoxide mediated inhibition of intimal hyperplasia$0
I01 · FY2013 · VA · contact PI
Vascular Surgery Research Training$391,215
T32 · FY2012 · HL · contact PI
Vascular Surgery Research Training$385,266
T32 · FY2011 · HL · contact PI
Carbon monoxide mediated inhibition of intimal hyperplasia$0
I01 · FY2011 · VA · contact PI
Vascular Surgery Research Training$187,015
T32 · FY2010 · HL · contact PI
Carbon monoxide mediated inhibition of intimal hyperplasia$0
I01 · FY2009 · VA · contact PI
iNOS Gene Therapy to Prevent AV Graft Intimal Hyperplasia$184,407
U01 · FY2005 · HL
Blocking Intimal Hyperplasia Following Vascular Trauma$287,261
R01 · FY2004 · HL
Blocking Intimal Hyperplasia Following Vascular Trauma$288,952
R01 · FY2003 · HL
iNOS gene therapy to prevent AV graft intimal hyperplasia$292,370
U01 · FY2002 · HL
iNOS gene therapy to prevent AV graft intimal hyperplasia$292,370
U01 · FY2002 · HL
Blocking Intimal Hyperplasia Following Vascular Trauma$290,130
R01 · FY2002 · HL
Blocking Intimal Hyperplasia Following Vascular Trauma$296,417
R01 · FY2001 · HL
iNOS gene therapy to prevent AV graft intimal hyperplasia$292,370
U01 · FY2001 · HL
iNOS gene therapy to prevent AV graft intimal hyperplasia$292,370
U01 · FY2001 · HL
iNOS gene therapy to prevent AV graft intimal hyperplasia$292,370
U01 · FY2000 · HL
BLOCKING INTIMAL HYPERPLASIA FOLLOWING VASCULAR TRAUMA$105,000
R29 · FY2000 · HL